Business
Hardman Research: Continuing to gain market share
Hardman Research: Continuing to gain market share.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 1249T Allergy Therapeutics PLC 10 October 2017 \n\nHardman Research: Continuing to gain market share\nContinuing to gain market share - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only on a 'Named Patient' basis. Investment in marketing over the last three years has been reflected in exceptional growth, with +10% CAGR in sales over the last five years compared to overall allergy vaccine market growth of +1%. In fiscal 2017, AGY gained another one-point market share to 13%. R&D investment in clinical trials for full approval as a biological in both Europe and the US are progressing with results due to be released in the second half of calendar 2018.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/10.10.17-continuing-to-gain-market-share.pdf\n\n\n\n\nTo contact us:\nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\nFollow us on Twitter @HardmanandCo\n\n\nContacts:\nDr Martin Hall\nDr Dorothea Hill\nDr Gregoire Pave\n \n+44 20 7194 7622\n\n\n \[email protected]\[email protected]\[email protected]\n \nwww.hardmanandco.com\n\n\n\n\nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and soph...